The negotiation of the national medical insurance drug catalogue in 2022 was officially concluded on January 8, 2023. This year, a total of three COVID-19 therapeutic drugs, Azovudine Tablets, Nematovir Tablets/Litonavir Tablets Combination Packaging (hereinafter referred to as "Paxlovid") and Qingfei Paidu Granules, participated in the negotiation. Paxlovid failed because of the high price quoted by the manufacturer Pfizer. Although it was not included in the medical insurance list through negotiation, all therapeutic drugs in the Diagnosis and Treatment Plan for novel coronavirus Infection (Tenth Edition for Trial Implementation), including Paxlovid, will be temporarily paid by the medical insurance until March 31, 2023. At present, there are more than 600 kinds of drugs in the national medical insurance drug list for the treatment of COVID-19 symptoms such as fever and cough. At the same time, in the near future, local medical insurance departments have temporarily included a batch of COVID-19 symptomatic drugs into the payment scope of local medical insurance in combination with the operation of local medical insurance funds. In general, there are a variety of drugs for COVID-19 infection treatment reimbursed by medical insurance. Prior to the centralized procurement and use of drugs nationwide, the "soul bargain" has won the attention and support of public opinion. In the process of fighting against the COVID-19, the National Medical Security Bureau adjusted the drug catalog in time and started the centralized procurement work again to play an effective role, reflecting the original intention of people first in the system design and the improvement of national governance ability. Drugs are not ordinary commodities. Because they involve the right to health and social ethics, the drug pricing mechanism is different from other commodities, and is usually called the drug price discovery mechanism. According to the object and scope of drug use, there are three pricing mechanisms: first, direct pricing by the government, such as vaccine procurement and nucleic acid testing. The second is the agreement pricing. The basic health care drugs paid by the social medical insurance fund belong to quasi-public goods and are priced through the negotiation mechanism. Third, market pricing covers niche and personalized drugs. The centralized purchase of drugs under the China Medical Security Fund belongs to the scope of agreement pricing. Medicine is expensive, and the value of medical insurance is to share the medical expenses of the insured patients, transform more than 1000 diseases and more than 2000 drugs into necessities, so that people can afford them. In 2010, the National People's Congress promulgated the Social Insurance Law of the People's Republic of China to regulate basic medical insurance. The report of the 18th CPC National Congress in 2012 proposed the goal of full coverage of social security. In January 2016, the State Council issued the Opinions on the Integration of the Basic Medical Insurance System for Urban and Rural Residents, putting forward the "six unifications" requirements for the integration of the medical insurance system policies for urban and rural residents. By the end of 2021, 1.36 billion people had participated in basic medical insurance nationwide, with a stable rate of more than 95%. The world's largest basic medical insurance system had been established. In November 2016, the Chinese government won the "Outstanding Achievement Award of Social Security of the International Social Security Association" issued by the International Social Security Association (ISSA), to commend the Chinese government for its outstanding achievements in the field of social security, especially in expanding the coverage of social security, significantly improving the level of social security and sustainable development of social security, with strong political commitment and many major management innovations. In the eight constitutions promulgated since the founding of the People's Republic of China, the keynote of the universal medical security has never changed. This is the CPC's commitment to